Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.
Kelsey Pan, MD, MPH
Advertisement
Kelsey Pan, MD, MPH, is the chief hematology/oncology fellow at MD Anderson Cancer Center.
Articles by Kelsey Pan, MD, MPH
Advertisement
Latest Updated Articles
Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLCPublished: June 19th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5